U.S. Stocks Movements: ImmunityBio surged on September 30 due to ANKTIVA expanded indications and FDA review

ImmunityBio September 30th Surge Analysis

Keywords: ANKTIVA expanded indications, FDA review

1. On September 30th, information was updated regarding ANKTIVA’s potential indication expansion, and the U.S. Food and Drug Administration intends to make a label expansion decision by January 6, 2027; the company’s September 11th patent application proposes combining ANKTIVA with checkpoint inhibitors, cancer vaccines, and engineered NK cells. Data from 98 non-small cell lung cancer cases shows a median survival of 21.1 months in patients with mild lymphocytopenia and 11.5 months in those with severe lymphocytopenia.

2. On September 30th, the GA-Courtenay Special Situations Fund highlighted ImmunityBio in its Q2 2026 investor letter; the company specializes in developing and commercializing next-generation immunotherapies, with its core Cancer BioShield platform based on the IL-15 superagonist ANKTIVA, covering natural killer cells, cytotoxic T cells, and memory T cells.

(Disclaimer: This content is generated by AI technology summarizing publicly available information for reference only, and does not constitute investment advice.)